

Alison M Mcdonnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3099775/publications.pdf>

Version: 2024-02-01

22
papers

590
citations

687363

13
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

1317
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-severe burn injury increases cancer incidence in mice and has long-term impacts on the activation and function of T cells. <i>Burns and Trauma</i> , 2022, 10, tkac016.	4.9	3
2	Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	3
3	Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. <i>Cells</i> , 2021, 10, 56.	4.1	14
4	A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 465-474.	2.4	1
5	Malignant Pleural Effusionsâ€”A Window Into Local Anti-Tumor T Cell Immunity?. <i>Frontiers in Oncology</i> , 2021, 11, 672747.	2.8	9
6	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. <i>Scientific Reports</i> , 2021, 11, 15312.	3.3	15
7	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	4.8	39
8	Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 565.	4.1	28
9	Diverse Anti-Tumor Immune Potential Driven by Individual IFNÎ± Subtypes. <i>Frontiers in Immunology</i> , 2020, 11, 542.	4.8	6
10	Immune checkpoint inhibition for the treatment of mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 697-706.	3.1	18
11	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. <i>BMC Research Notes</i> , 2018, 11, 864.	1.4	7
12	Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. <i>BMC Cancer</i> , 2017, 17, 417.	2.6	8
13	Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. <i>Oncolmmunology</i> , 2016, 5, e1066062.	4.6	55
14	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. <i>Lung Cancer</i> , 2016, 93, 9-16.	2.0	27
15	Tumorâ€”infiltrating dendritic cells exhibit defective crossâ€”presentation of tumor antigens, but is reversed by chemotherapy. <i>European Journal of Immunology</i> , 2015, 45, 49-59.	2.9	64
16	A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. <i>Annals of Oncology</i> , 2015, 26, 2483-2490.	1.2	76
17	Restoration of defective cross-presentation in tumors by gemcitabine. <i>Oncolmmunology</i> , 2015, 4, e1005501.	4.6	16
18	Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. <i>Oncolmmunology</i> , 2012, 1, 840-846.	4.6	21

#	ARTICLE	IF	CITATIONS
19	Contribution of the immune system to the chemotherapeutic response. <i>Seminars in Immunopathology</i> , 2011, 33, 353-367.	6.1	30
20	CD8 ⁺ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. <i>European Journal of Immunology</i> , 2010, 40, 1617-1627.	2.9	33
21	Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-9.	3.3	59
22	Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation. <i>Journal of Immunology</i> , 2009, 183, 7898-7908.	0.8	58